Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31305414 | 0.94 | DRD2 (0.50) | DRD2SIGMAR1CACNA1HTDP1 | |
| SCHEMBL30572359 | 0.89 | DRD2 (0.45) | DRD2SIGMAR1CACNA1H | |
| SCHEMBL31305369 | 0.88 | DRD2 (0.46) | DRD2SIGMAR1CACNA1HTDP1 | |
| SCHEMBL21069638 | 0.86 | DRD2 (0.46) | DRD2SIGMAR1CACNA1HTDP1 | |
| SCHEMBL28927100 | 0.86 | MEN1 (0.49) | DRD2SIGMAR1CACNA1HTDP1 | |
| SCHEMBL4024516 | 0.85 | DRD2 (0.56) | DRD2ACHEBACE1CACNA1HTDP1 | |
| SCHEMBL4743239 | 0.84 | ACHE (0.58) | DRD2ACHEBACE1SIGMAR1TDP1 | |
| Iodide SCHEMBL15145961 | 0.84 | DRD2 (0.57) | DRD2ACHEBACE1SIGMAR1TDP1 | |
| SCHEMBL485945 | 0.83 | DRD2 (0.55) | DRD2ACHEBACE1CACNA1HTDP1 | |
| SCHEMBL7220892 | 0.83 | DRD2 (0.55) | DRD2ACHEBACE1CACNA1HTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858648-B2 | Nanotube complexes are water soluble, nontoxic; use in delivering biologicals such as DNA for gene therapy, DNA vaccines; amine salts derived from diethylenetriaminepentaacetic acid-modified nanotubes with anion such as DNA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2010-12-28 | — | — | US | disclosed |
| US-20080076816-A1 | Nanotube complexes are water soluble, nontoxic; use in delivering biologicals such as DNA for gene therapy, DNA vaccines; amine salts derived from diethylenetriaminepentaacetic acid-modified nanotubes with anion such as DNA | THE UNIVERSITY OF MANCHESTER (GB) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076816-A1 | Nanotube complexes are water soluble, nontoxic; use in delivering biologicals such as DNA for gene therapy, DNA vaccines; amine salts derived from diethylenetriaminepentaacetic acid-modified nanotubes with anion such as DNA | DNTT, EEA1, DCTN1 | DRD2 2115/4885ACHE 3790/4885BACE1 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.